Alkylating agents
Hepatic Arterial Infusion + Chemotherapy for Colorectal Cancer Liver Metastases
Recruiting1 awardPhase 1
New Brunswick, New Jersey
This trial is testing a new cancer treatment for people who have had part of their liver removed. It's a combination of two drugs given through an IV, plus a third drug given through a pump that goes directly to the liver. The goal is to find the best dose of each drug to give, based on how well the patient tolerates the treatment.
PD-1/PD-L1 Checkpoint Inhibitor
Combination Immunotherapy for Cancer
Recruiting1 awardPhase 2
Hot Springs, Arkansas
This trial tests a combination of treatments that aim to boost the immune system in patients whose cancer has progressed after previous treatments. Some patients may receive an additional therapy if their disease continues to progress.
Chemotherapy
Chemotherapy + Bevacizumab + Tumor Treating Fields Therapy for Liver Cancer
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing a new combination of chemotherapy drugs with bevacizumab, and a new portable device that uses electrical fields to stop the growth of tumor cells, in people with cancer that has come back or does not respond to treatment and has spread to the liver.
Checkpoint Inhibitor
Nivolumab + Ipilimumab + Radiation for Colorectal and Pancreatic Cancer
Recruiting2 awardsPhase 2
Boston, Massachusetts
This trial is studying a combination of drugs as a possible treatment for certain types of cancer. The drugs are Nivolumab and Ipilimumab, and the radiation therapy is meant to target the cancer specifically.
Popular Filters
Trials for Colon Cancer Patients
PARP Inhibitor
Durvalumab + Olaparib + Cediranib for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial is testing the combination of Durvalumab, Olaparib, and Cediranib in adults with advanced or recurrent ovarian cancer to see how well they tolerate it and if it is effective in treating the cancer.
Kinase Inhibitor
Triple Therapy for Advanced Solid Cancers
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing the side effects and best dose of vemurafenib when given with cetuximab and irinotecan hydrochloride to treat patients with solid tumors. Vemurafenib and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Trials for Colorectal Cancer Patients
PARP Inhibitor
Durvalumab + Olaparib + Cediranib for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial is testing the combination of Durvalumab, Olaparib, and Cediranib in adults with advanced or recurrent ovarian cancer to see how well they tolerate it and if it is effective in treating the cancer.
Kinase Inhibitor
Triple Therapy for Advanced Solid Cancers
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing the side effects and best dose of vemurafenib when given with cetuximab and irinotecan hydrochloride to treat patients with solid tumors. Vemurafenib and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Trials for BRAF Positive Patients
PARP Inhibitor
Durvalumab + Olaparib + Cediranib for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial is testing the combination of Durvalumab, Olaparib, and Cediranib in adults with advanced or recurrent ovarian cancer to see how well they tolerate it and if it is effective in treating the cancer.
Kinase Inhibitor
Triple Therapy for Advanced Solid Cancers
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing the side effects and best dose of vemurafenib when given with cetuximab and irinotecan hydrochloride to treat patients with solid tumors. Vemurafenib and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Monoclonal Antibodies
Encorafenib + Cetuximab + Nivolumab for Colorectal Cancer
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial is testing a combination of drugs to treat patients with colorectal cancer that has spread and cannot be removed by surgery. The drugs work by blocking enzymes needed for cell growth and by helping the body's immune system attack the cancer.
Checkpoint Inhibitor
Regorafenib + Immunotherapy for Colorectal Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial is studying regorafenib in combination with ipilimumab and nivolumab to see if it can help to treat patients with colorectal cancer that has spread and is resistant to chemotherapy.
Kinase Inhibitor
Encorafenib + Cetuximab for Colorectal Cancer
Recruiting2 awardsPhase 3
Duarte, California
This trial is testing a new combination of drugs to treat colorectal cancer that has spread and has a certain type of abnormal gene. The new combination is encorafenib plus cetuximab, which will be taken either alone or with standard chemotherapy.
Trials for KRAS Positive Patients
Checkpoint Inhibitor
Cancer Vaccine + Nivolumab + Ipilimumab for Pancreatic and Colorectal Cancer
Recruiting1 awardPhase 1
Baltimore, Maryland
This trial tests a special vaccine combined with immune-boosting drugs for patients with advanced pancreatic or colorectal cancer who have had extensive prior treatments. The goal is to train and enhance the immune system to better fight cancer. The vaccine has been used in previous studies to help the immune system recognize cancer cells in pancreatic cancer patients.
KRAS G12C Inhibitor
GDC-6036 for KRAS G12C-Mutated Cancers
Recruiting1 awardPhase 1
La Jolla, California
This trial is testing a new drug called GDC-6036 in patients with advanced or metastatic solid tumors that have a KRAS G12C mutation. The drug works by blocking a faulty part of the cancer cells' genetic code to stop their growth.
Small Molecule
MRTX849 + Cetuximab for Colorectal Cancer
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing a new treatment for patients with colorectal cancer. The treatment combines two drugs that work together to block cancer growth and prevent its spread. One of the drugs has shown promise in treating other types of cancer as well.
Phase 3 Trials
Chemotherapy
Vitamin D3 + Chemotherapy + Bevacizumab for Colorectal Cancer
Recruiting2 awardsPhase 3
Birmingham, Alabama
This trial is testing if vitamin D3 along with regular cancer drugs and another drug that helps the immune system can better treat colorectal cancer that has spread. Vitamin D3 may help the body use essential minerals, making the cancer drugs more effective. Vitamin D3 has been shown to slow down cancer cell growth and help them mature, and it has been effective in reducing intestinal tumors in animal studies.
Chemotherapy
Nivolumab + Ipilimumab for Colorectal Cancer
Recruiting2 awardsPhase 3
Los Angeles, California
This trial is testing nivolumab with or without ipilimumab as a treatment for metastatic colorectal cancer in patients with microsatellite instability high or mismatch repair deficiency. The goal is to see if the combination therapy is more effective than nivolumab alone and if either treatment is more effective than chemotherapy.
Trials With No Placebo
PARP Inhibitor
Durvalumab + Olaparib + Cediranib for Ovarian Cancer
Recruiting1 awardPhase 1 & 2
Bethesda, Maryland
This trial is testing the combination of Durvalumab, Olaparib, and Cediranib in adults with advanced or recurrent ovarian cancer to see how well they tolerate it and if it is effective in treating the cancer.
Kinase Inhibitor
Triple Therapy for Advanced Solid Cancers
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing the side effects and best dose of vemurafenib when given with cetuximab and irinotecan hydrochloride to treat patients with solid tumors. Vemurafenib and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cetuximab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Chemotherapy
Ursodiol + Chemotherapy + Bevacizumab for Colorectal Cancer
Recruiting3 awardsPhase 1
Duarte, California
This trial is studying the side effects and best dose of the drug ursodiol when given together with combination chemotherapy (leucovorin calcium, fluorouracil, and oxaliplatin) and bevacizumab in treating patients with stage IV colorectal cancer.
Corticosteroid
Chemotherapy + Hepatic Arterial Infusion for Colorectal Cancer
Recruiting1 awardPhase 2
Basking Ridge, New Jersey
This trial is studying a treatment for colorectal cancer that has spread to the liver. The treatment is a combination of chemotherapy drugs and two other drugs, given directly into the arteries around the tumor.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.